VYNE Therapeutics (NASDAQ:VYNE) Upgraded by Zacks Investment Research to “Hold”

VYNE Therapeutics (NASDAQ:VYNEGet Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report issued on Wednesday, Zacks.com reports.

According to Zacks, “VYNE Therapeutics Inc. focuses on developing and commercializing therapeutics for dermatology. The company’s product pipeline consist FMX103 and FCD105 which are in clinical stage. VYNE Therapeutics Inc., formerly known as Menlo Therapeutics Inc., is based in Bridgewater, New Jersey. “

Separately, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of VYNE Therapeutics in a report on Friday, March 18th.

Shares of NASDAQ:VYNE traded up $0.01 during trading on Wednesday, hitting $0.55. The company’s stock had a trading volume of 3,594 shares, compared to its average volume of 1,182,445. The firm has a market cap of $30.89 million, a price-to-earnings ratio of -0.38 and a beta of 0.96. The company has a 50-day moving average of $0.60 and a 200-day moving average of $0.92. VYNE Therapeutics has a 12 month low of $0.46 and a 12 month high of $5.97.

VYNE Therapeutics (NASDAQ:VYNEGet Rating) last announced its earnings results on Thursday, March 17th. The company reported ($0.20) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.25) by $0.05. VYNE Therapeutics had a negative net margin of 496.98% and a negative return on equity of 106.54%. On average, equities research analysts forecast that VYNE Therapeutics will post -0.67 EPS for the current year.

A number of hedge funds and other institutional investors have recently bought and sold shares of VYNE. SkyOak Wealth LLC purchased a new position in shares of VYNE Therapeutics in the fourth quarter worth $28,000. Susquehanna International Group LLP boosted its holdings in shares of VYNE Therapeutics by 217.1% during the 4th quarter. Susquehanna International Group LLP now owns 45,330 shares of the company’s stock valued at $46,000 after purchasing an additional 31,033 shares during the last quarter. Staley Capital Advisers Inc. grew its position in shares of VYNE Therapeutics by 33.3% during the third quarter. Staley Capital Advisers Inc. now owns 50,000 shares of the company’s stock valued at $70,000 after purchasing an additional 12,500 shares in the last quarter. Thrivent Financial for Lutherans increased its holdings in shares of VYNE Therapeutics by 20.2% in the third quarter. Thrivent Financial for Lutherans now owns 71,990 shares of the company’s stock worth $101,000 after purchasing an additional 12,106 shares during the last quarter. Finally, Two Sigma Investments LP increased its stake in VYNE Therapeutics by 72.9% in the 3rd quarter. Two Sigma Investments LP now owns 81,287 shares of the company’s stock worth $113,000 after acquiring an additional 34,262 shares during the last quarter. 26.73% of the stock is currently owned by institutional investors.

VYNE Therapeutics Company Profile (Get Rating)

VYNE Therapeutics, Inc engages in the manufacture of pharmaceutical products. It develops and commercialize solutions using its proprietary Molecule Stabilizing Technology. Its commercial products include AMZEEQ and ZILXI. The company is headquartered in Bridgewater, NJ.

See Also

Get a free copy of the Zacks research report on VYNE Therapeutics (VYNE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for VYNE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VYNE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.